🚀 VC round data is live in beta, check it out!
Caris Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Caris Life Sciences and similar public comparables like CRISPR Therapeutics, Bruker, SK Biopharmaceuticals, Lundbeck and more.
Caris Life Sciences Overview
About Caris Life Sciences
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Founded
2008
HQ
Employees
1.8K
Website
Financials (LTM)
EV
$6B
Caris Life Sciences Financials
Caris Life Sciences reported last 12-month revenue of $854M and EBITDA of $143M.
In the same LTM period, Caris Life Sciences generated $566M in gross profit, $143M in EBITDA, and had net loss of ($45M).
Revenue (LTM)
Caris Life Sciences P&L
In the most recent fiscal year, Caris Life Sciences reported revenue of $812M and EBITDA of $138M.
Caris Life Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $854M | XXX | $812M | XXX | XXX | XXX |
| Gross Profit | $566M | XXX | $539M | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | $143M | XXX | $138M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | ($45M) | XXX | ($68M) | XXX | XXX | XXX |
| Net Margin | (5%) | XXX | (8%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Caris Life Sciences Stock Performance
Caris Life Sciences has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
Caris Life Sciences' stock price is $20.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | 0.0% | XXX | XXX | XXX | $-0.24 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCaris Life Sciences Valuation Multiples
Caris Life Sciences trades at 6.4x EV/Revenue multiple, and 38.4x EV/EBITDA.
EV / Revenue (LTM)
Caris Life Sciences Financial Valuation Multiples
As of March 20, 2026, Caris Life Sciences has market cap of $6B and EV of $6B.
Equity research analysts estimate Caris Life Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Caris Life Sciences has a P/E ratio of (129.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 6.4x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | 38.4x | XXX | 39.9x | XXX | XXX | XXX |
| EV/EBIT | 98.7x | XXX | 121.9x | XXX | XXX | XXX |
| EV/Gross Profit | 9.7x | XXX | 10.2x | XXX | XXX | XXX |
| P/E | (129.3x) | XXX | (85.6x) | XXX | XXX | XXX |
| EV/FCF | 84.9x | XXX | 82.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Caris Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Caris Life Sciences Margins & Growth Rates
Caris Life Sciences' revenue in the last 12 month grew by 24%.
Caris Life Sciences' revenue per employee in the last FY averaged $0.5M.
Caris Life Sciences' rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Caris Life Sciences' rule of X is 76% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Caris Life Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 27% | XXX | 28% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Caris Life Sciences Public Comps
See public comps and valuation multiples for other Medical Devices and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CRISPR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Bruker | XXX | XXX | XXX | XXX | XXX | XXX |
| SK Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Lundbeck | XXX | XXX | XXX | XXX | XXX | XXX |
| NewMarket | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Caris Life Sciences M&A Activity
Caris Life Sciences acquired XXX companies to date.
Last acquisition by Caris Life Sciences was on XXXXXXXX, XXXXX. Caris Life Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Caris Life Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCaris Life Sciences Investment Activity
Caris Life Sciences invested in XXX companies to date.
Caris Life Sciences made its latest investment on XXXXXXXX, XXXXX. Caris Life Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Caris Life Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Caris Life Sciences
| When was Caris Life Sciences founded? | Caris Life Sciences was founded in 2008. |
| Where is Caris Life Sciences headquartered? | Caris Life Sciences is headquartered in United States. |
| How many employees does Caris Life Sciences have? | As of today, Caris Life Sciences has over 1K employees. |
| Who is the CEO of Caris Life Sciences? | Caris Life Sciences' CEO is David D. Halbert. |
| Is Caris Life Sciences publicly listed? | Yes, Caris Life Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Caris Life Sciences? | Caris Life Sciences trades under CAI ticker. |
| When did Caris Life Sciences go public? | Caris Life Sciences went public in 2025. |
| Who are competitors of Caris Life Sciences? | Caris Life Sciences main competitors are CRISPR Therapeutics, Bruker, SK Biopharmaceuticals, Lundbeck. |
| What is the current market cap of Caris Life Sciences? | Caris Life Sciences' current market cap is $6B. |
| What is the current revenue of Caris Life Sciences? | Caris Life Sciences' last 12 months revenue is $854M. |
| What is the current revenue growth of Caris Life Sciences? | Caris Life Sciences revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of Caris Life Sciences? | Current revenue multiple of Caris Life Sciences is 6.4x. |
| Is Caris Life Sciences profitable? | Yes, Caris Life Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Caris Life Sciences? | Caris Life Sciences' last 12 months EBITDA is $143M. |
| What is Caris Life Sciences' EBITDA margin? | Caris Life Sciences' last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Caris Life Sciences? | Current EBITDA multiple of Caris Life Sciences is 38.4x. |
| What is the current FCF of Caris Life Sciences? | Caris Life Sciences' last 12 months FCF is $65M. |
| What is Caris Life Sciences' FCF margin? | Caris Life Sciences' last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Caris Life Sciences? | Current FCF multiple of Caris Life Sciences is 84.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.